Abstract
Background: Monoamine oxidase‐B (MAO‐B) is a pivotal enzyme in the pathophysiology of Parkinson’s disease (PD), where its elevated activity accelerates dopamine catabolism, increases oxidative stress and contributes to the progressive loss of dopaminergic neurons. This study investigates the MAO‐B inhibitory potential of a series of pyrazole‐based chalcone derivatives using an integrated computational framework. Methods: A ligand library was generated through R‐group enumeration and screened for physicochemical suitability and pharmacokinetic compliance. Molecular docking against MAO‐B (PDB ID: 2BYB) was performed to evaluate binding affinity, which was further validated through MM‐GBSA binding free‐energy calculations. Pharmacophore modelling using Phase identified the key structural features governing MAO‐B inhibition. The top‐ranked complexes were subjected to molecular dynamics simulations to assess structural stability. Density functional theory (DFT) calculations were conducted to examine electronic reactivity, including HOMO–LUMO gaps and related quantum descriptors. Results: The designed ligands demonstrated favourable physicochemical and pharmacokinetic profiles. Docking studies indicated strong binding affinities, with several compounds outperforming the reference inhibitor deprenyl, consistent with MM‐GBSA predictions. Pharmacophore modelling revealed a five‐point AHHRR_1 hypothesis as the critical determinant of activity. Hydrophobic 3,5‐dimethyl substitutions on the pyrazole ring enhanced electron density and inhibitory potency, while the conjugated π‐system between pyrazole and phenyl moieties contributed to stabilised π–π interactions. Para‐substituted electron‐withdrawing groups on the phenyl ring further improved MAO‐B selectivity. Molecular dynamics simulations confirmed robust complex stability, with the 5b/2BYB complex exhibiting low RMSD, minimal residue fluctuations and persistent hydrogen‐bonding and hydrophobic contacts. DFT analysis revealed narrow HOMO–LUMO gaps, indicative of high electronic reactivity and strong binding propensity. Conclusion: Overall, this comprehensive computational investigation offers valuable insights for the rational design and optimisation of pyrazole–chalcone derivatives as promising MAO‐B inhibitors for PD therapy and supports their further in vitro and in vivo evaluation.

This publication has 84 references indexed in Scilit: